Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Obseva SA (NASDAQ:OBSV) during the third quarter, HoldingsChannel reports. The firm purchased 48,911 shares of the company’s stock, valued at approximately $882,000.
Other large investors also recently modified their holdings of the company. US Bancorp DE acquired a new stake in Obseva during the second quarter worth approximately $197,000. Tiverton Asset Management LLC acquired a new stake in Obseva during the second quarter worth approximately $224,000. Jane Street Group LLC acquired a new stake in Obseva during the second quarter worth approximately $349,000. DRW Securities LLC boosted its holdings in shares of Obseva by 55.0% in the 2nd quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock valued at $512,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Obseva in the 2nd quarter valued at $519,000. 72.19% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ OBSV opened at $14.83 on Thursday. Obseva SA has a twelve month low of $9.05 and a twelve month high of $20.35. The firm has a market cap of $540.35 million, a P/E ratio of -6.59 and a beta of 1.65.
Obseva (NASDAQ:OBSV) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.04. Research analysts forecast that Obseva SA will post -1.86 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Obseva from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Leerink Swann started coverage on Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 target price on the stock. HC Wainwright set a $44.00 price objective on Obseva and gave the company a “buy” rating in a report on Wednesday, August 8th. JPMorgan Chase & Co. started coverage on Obseva in a report on Thursday, September 13th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, TheStreet raised Obseva from a “d+” rating to a “c-” rating in a report on Thursday, October 11th. Eight research analysts have rated the stock with a buy rating, Obseva has an average rating of “Buy” and an average price target of $29.43.
COPYRIGHT VIOLATION NOTICE: “Zurcher Kantonalbank Zurich Cantonalbank Purchases New Stake in Obseva SA (OBSV)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/12/06/zurcher-kantonalbank-zurich-cantonalbank-purchases-new-stake-in-obseva-sa-obsv.html.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding OBSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Obseva SA (NASDAQ:OBSV).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.